BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Loh AHP, Stewart E, Bradley CL, Chen X, Daryani V, Stewart CF, Calabrese C, Funk A, Miller G, Karlstrom A, Krafcik F, Goshorn DR, Vogel P, Bahrami A, Shelat A, Dyer MA. Combinatorial screening using orthotopic patient derived xenograft-expanded early phase cultures of osteosarcoma identify novel therapeutic drug combinations. Cancer Lett 2019;442:262-70. [PMID: 30395907 DOI: 10.1016/j.canlet.2018.10.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Pierrevelcin M, Fuchs Q, Lhermitte B, Messé M, Guérin E, Weingertner N, Martin S, Lelong-Rebel I, Nazon C, Dontenwill M, Entz-Werlé N. Focus on Hypoxia-Related Pathways in Pediatric Osteosarcomas and Their Druggability. Cells 2020;9:E1998. [PMID: 32878021 DOI: 10.3390/cells9091998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Castillo-Tandazo W, Mutsaers AJ, Walkley CR. Osteosarcoma in the Post Genome Era: Preclinical Models and Approaches to Identify Tractable Therapeutic Targets. Curr Osteoporos Rep 2019;17:343-52. [PMID: 31529263 DOI: 10.1007/s11914-019-00534-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
3 Schott C, Shah AT, Sweet-Cordero EA. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies. Adv Exp Med Biol 2020;1258:1-19. [PMID: 32767231 DOI: 10.1007/978-3-030-43085-6_1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Kamili A, Gifford AJ, Li N, Mayoh C, Chow SO, Failes TW, Eden GL, Cadiz R, Xie J, Lukeis RE, Norris MD, Haber M, McCowage GB, Arndt GM, Trahair TN, Fletcher JI. Accelerating development of high-risk neuroblastoma patient-derived xenograft models for preclinical testing and personalised therapy. Br J Cancer 2020;122:680-91. [PMID: 31919402 DOI: 10.1038/s41416-019-0682-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
5 Geng A, Cui H, Zhang L, Chen X, Li H, Lu T, Zhu Y. Discovery of novel phenoxybenzamide analogues as Raf/HDAC dual inhibitors. Bioorganic & Medicinal Chemistry Letters 2019;29:1605-8. [DOI: 10.1016/j.bmcl.2019.04.047] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
6 Jiang Y, Wang G, Mu H, Ma X, Wang Z, Lv Y, Zhang T, Xu J, Wang J, Li Y, Han J, Yang M, Wang Z, Zeng K, Jin X, Xue S, Yin M, Sun W, Hua Y, Cai Z. Bromodomain Inhibition Attenuates the Progression and Sensitizes the Chemosensitivity of Osteosarcoma by Repressing GP130/STAT3 Signaling. Front Oncol 2021;11:642134. [PMID: 34168981 DOI: 10.3389/fonc.2021.642134] [Reference Citation Analysis]
7 Byrgazov K, Anderson C, Salzer B, Bozsaky E, Larsson R, Gullbo J, Lehner M, Lehmann F, Slipicevic A, Kager L, Fryknäs M, Taschner-Mandl S. Targeting aggressive osteosarcoma with a peptidase-enhanced cytotoxic melphalan flufenamide. Ther Adv Med Oncol 2020;12:1758835920937891. [PMID: 32774473 DOI: 10.1177/1758835920937891] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Torres HM, VanCleave AM, Vollmer M, Callahan DL, Smithback A, Conn JM, Rodezno-Antunes T, Gao Z, Cao Y, Afeworki Y, Tao J. Selective Targeting of Class I Histone Deacetylases in a Model of Human Osteosarcoma. Cancers (Basel) 2021;13:4199. [PMID: 34439353 DOI: 10.3390/cancers13164199] [Reference Citation Analysis]
9 Collier CD, Getty PJ, Greenfield EM. Targeting the Cancer Epigenome with Histone Deacetylase Inhibitors in Osteosarcoma. Adv Exp Med Biol 2020;1258:55-75. [PMID: 32767234 DOI: 10.1007/978-3-030-43085-6_4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
10 Landuzzi L, Manara MC, Lollini PL, Scotlandi K. Patient Derived Xenografts for Genome-Driven Therapy of Osteosarcoma. Cells 2021;10:416. [PMID: 33671173 DOI: 10.3390/cells10020416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
11 Bass AKA, El-Zoghbi MS, Nageeb EM, Mohamed MFA, Badr M, Abuo-Rahma GEA. Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. Eur J Med Chem 2021;209:112904. [PMID: 33077264 DOI: 10.1016/j.ejmech.2020.112904] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Ji XL, He M. Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma. Aging (Albany NY) 2019;11:5848-63. [PMID: 31422383 DOI: 10.18632/aging.102193] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Whittle SB, Offer K, Roberts RD, LeBlanc A, London C, Majzner RG, Huang AY, Houghton P, Alejandro Sweet Cordero E, Grohar PJ, Isakoff M, Bishop MW, Stewart E, Slotkin EK, Greengard E, Borinstein SC, Navid F, Gorlick R, Janeway KA, Reed DR, Hingorani P. Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task Force. Pediatr Blood Cancer 2021;68:e29188. [PMID: 34137164 DOI: 10.1002/pbc.29188] [Reference Citation Analysis]
14 McGuire JJ, Nerlakanti N, Lo CH, Tauro M, Utset-Ward TJ, Reed DR, Lynch CC. Histone deacetylase inhibition prevents the growth of primary and metastatic osteosarcoma. Int J Cancer 2020;147:2811-23. [PMID: 32599665 DOI: 10.1002/ijc.33046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
15 Yu X, Yustein JT, Xu J. Research models and mesenchymal/epithelial plasticity of osteosarcoma. Cell Biosci 2021;11:94. [PMID: 34022967 DOI: 10.1186/s13578-021-00600-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]